Amonafide (originally AS1413) (
INN
Inns are generally establishments or buildings where travelers can seek lodging, and usually, food and drink. Inns are typically located in the country or along a highway. Before the advent of motorized transportation, they also provided accomm ...
, trade names Quinamed and Xanafide) was a drug that was being studied in the treatment of
cancer
Cancer is a group of diseases involving Cell growth#Disorders, abnormal cell growth with the potential to Invasion (cancer), invade or Metastasis, spread to other parts of the body. These contrast with benign tumors, which do not spread. Po ...
. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential
topoisomerase inhibitor
Topoisomerase inhibitors are chemical compounds that block the action of topoisomerases, which are broken into two broad subtypes: type I topoisomerases (TopI) and type II topoisomerases (TopII). Topoisomerase plays important roles in cellular rep ...
and
DNA intercalator.
It was being developed as an anti-cancer therapy by
Antisoma.
, it is in
Phase III clinical trial
Clinical trials are prospective biomedical or behavioral research studies on human subject research, human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel v ...
s.
e.g. In March 2010 it is
Phase III trial against secondary
acute myeloid leukaemia
Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cell production. Symptoms may inclu ...
(AML).
In June 2010, it gained an FDA Fast Track Status for the treatment of Secondary Acute Myeloid Leukaemia.
See also
*
Alrestatin
References
External links
Amonafideentry in the public domain NCI Dictionary of Cancer Terms
Clinical trials of amonafideat ClinicalTrials.gov
Experimental cancer drugs
{{antineoplastic-drug-stub